Nature Reviews Cancer contents November 2014 Volume 14 Number 11 pp701-762

If you are unable to see the message below, click here to view.

Advertisement
CRISPR/Cas9 monoclonal antibody now available Diagenode now offers the first monoclonal antibody against CRISPR/Cas9 Better performance that tag antibodies Validated for all major applications such as immunoblot, immunoprecipitation, and IF Recognizes Cas9 and dCas9 Learn more
TABLE OF CONTENTS
November 2014 Volume 14 Number 11		Advertisement
Impact Factor 37.912 *	In this issue Comment Research Highlights Reviews Perspectives Also this month Article series: Clinical insights Featured article: Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Simran S. Sabharwal & Paul T. Schumacker	Tumor Immunology and Immunotherapy: A New Chapter Join us December 1-4 in Orlando, FL for this AACR Special Conference which will provide highly stimulating discussions on advances in basic and translational tumor immunology among basic cancer immunologists, non-immunologists, and clinical scientists. Learn more.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Reviews Clinical Oncology  FREE POSTER: Breast Cancer intrinsic subtypes This special Poster highlights recent achievements and development of our genetic understanding of the intrinsic subtypes of molecular breast cancer subtypes. Produced with support from:  NanoString® Technologies, Inc
Article series: Clinical insights Comment: Shouldn't we care about the biology of benign tumours? Adrian Marino-Enriquez & Christopher D. M. Fletcher p701 | doi:10.1038/nrc3845 This Comment article argues that we should more comprehensively study the biology of benign tumours, as this might provide crucial insights into our understanding of cancer biology and metastasis. Abstract | Full Text | PDF | Supplementary information
RESEARCH HIGHLIGHTS Top Metastasis: Metabolic reprogramming in disseminated cells p703 | doi:10.1038/nrc3842 LeBleu et al. show that the metabolism of migratory and circulating tumour cells is different to that of primary tumour cells and this difference enables migration and metastasis. PDF Angiogenesis: Pushing through, branching out p704 | doi:10.1038/nrc3841 Blood vessel branching during tumour angiogenesis is mediated by the formation of podosome rosettes. PDF Microenvironment: Source influences function p704 | doi:10.1038/nrc3843 Several tumour-promoting roles of cathepsin Z (CTSZ) in pancreatic neuroendocrine tumours (PanNETs) depend on its RGD motif, and CTSZ derived from tumour cells or tumour-associated macrophages has different functions. PDF Leukaemia: Fine-tuning metabolism p705 | doi:10.1038/nrc3839 Wang et al. show differential requirements for the glycolytic enzymes pyruvate kinase M2 and lactate dehydrogenase A in maintaining haematopoietic stem cells and progenitor cells. Although this difference does not seem to apply to leukaemias derived from these two different cell populations, leukaemia cells are more sensitive to glycolysis inhibition than normal cells. PDF Metabolism: Reprogramming metabolic flux in glioma p706 | doi:10.1038/nrc3840 Chen et al. have shown that growth of isocitrate dehydrogenase 1 (IDH1)-mutant gliomas is promoted by expression of glutamate dehydrogenase 2 (GLUD2) protein. PDF Tumorigenesis: Establishing the origin of retinoblastoma p706 | doi:10.1038/nrc3849 Xu et al. have identified the cell of origin of retinoblastoma and the cell type-specific circuitry that these tumour cells rely on. PDF IN BRIEF Tumorigenesis: BOC's plot thickens | Therapeutics: Delivered in a tea bag | Imaging: Marking the boundaries | Proteomics: Follow your heat | Genomic instability: SPRTN links cancer and ageing | Pancreatic cancer: Stromal modulation to prevent resistance | Lymphoma: Release the B cell | Tumorigenesis: Why melanoma? PDF Cancer JOBS of the week Postdoctoral Fellow - Breast Cancer Research Albert Einstein College of Medicine in New York Postdoctoral Fellow: Gene Regulation in Breast Cancer / Stem Cell Biology UC College of Medicine Cancer Biologist Wake Forest Baptist Medical Center 4 Year PhD Cancer Research PhD Studentship Cancer Research UK Manchester Institute Post-Docs in Cell Death Signaling & Cancer Goethe-Universität Frankfurt am Main More Science jobs from Cancer EVENT Radiation Biology and Cancer: From Molecular Responses to the Clinic 07.02.15 Essen, Germany More science events from
REVIEWS		Top
Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Simran S. Sabharwal & Paul T. Schumacker p709 | doi:10.1038/nrc3803 Reactive oxygen species (ROS) are generated through various mechanisms. Accumulating evidence indicates that these moieties have important roles in promoting tumorigenesis and tumour progression; modulating the redox balance could be a strategy in targeting cancer. Abstract | Full Text | PDF
Translational biology of osteosarcoma Maya Kansara, Michele W. Teng, Mark J. Smyth & David M. Thomas p722 | doi:10.1038/nrc3838 Survival for patients with metastatic or relapsed osteosarcoma has remained virtually unchanged during the past 30 years, and new therapeutic options are needed. This Review discusses normal bone biology relevant to osteosarcoma, including the immunobiology of bone, model systems for studying osteosarcoma, genetic and genomic studies on germline predisposition and tumour landscapes, and recent clinical trials. Abstract | Full Text | PDF | Supplementary information
Revisiting STAT3 signalling in cancer: new and unexpected biological functions Hua Yu, Heehyoung Lee, Andreas Herrmann, Ralf Buettner & Richard Jove p736 | doi:10.1038/nrc3818 The Janus kinases (JAKs) are major activators of signal transducer and activator of transcription (STAT) proteins, and this signalling axis is crucial for cancer development in both tumour cells and the tumour microenvironment. This Review discusses the new roles of JAK-STAT signalling in promoting cancer through inflammation, obesity, stem cells and the pre-metastatic niche, and the potential therapeutic strategies that these roles can offer. Abstract | Full Text | PDF
Advertisement
Pure epigenetics innovation. Unique validated antibodies and ChIP-seq expertise: Only provider of CAS9/CRISPR antibody Hundreds of validated antibodies for ChIP-seq ChIP-seq from just 10,000 cells
PERSPECTIVES		Top
OPINION Poised epigenetic states and acquired drug resistance in cancer Robert Brown, Edward Curry, Luca Magnani, Charlotte S. Wilhelm-Benartzi & Jane Borley p747 | doi:10.1038/nrc3819 Brown et al. argue that epigenetic heterogeneity leads to therapeutic resistance, such that bivalently marked gene promoters result in epigenetically poised gene expression that can become fixed by exposure to therapy. What are the opportunities to target this proposed mechanism of therapeutic resistance? Abstract | Full Text | PDF | Supplementary information
OPINION Cancer cachexia: understanding the molecular basis Josep M. Argilés, Sílvia Busquets, Britta Stemmler & Francisco J. López-Soriano p754 | doi:10.1038/nrc3829 Cancer cachexia is a multifactorial syndrome that affects many cancer patients and that leads to substantial weight loss, primarily from loss of skeletal muscle and body fat. This Opinion article focuses on the molecular mechanisms underlying cancer cachexia, in hopes that a better understanding of these might lead to improved therapeutic approaches. Abstract | Full Text | PDF
Advertisement
The Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Nature Genetics, and Nature Reviews Cancer present: Nuclear Reprogramming and the Cancer Genome 2014 October 31- November 2, 2014 Ramada Plaza, Guangzhou, China   Click here for more information or to register for this conference today!
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.